Prescribing information

 

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

You can access the MAYZENT materials below, which have been designed to support you and your SPMS patients. These materials will provide you with more in-depth information about MAYZENT, and support you in the day-to-day management of patients receiving MAYZENT.

 

Thumbnail of GP letter.
 

GP LETTER

A letter for GPs of patients who have been prescribed MAYZENT, detailing information relevant to primary care.

Preview

Thumbnail of CYP2C9 drug-drug interactions leaflet.
 

CYP2C9 DRUG-DRUG INTERACTIONS LEAFLET

A leaflet detailing recommendations regarding interactions with the cytochrome P450 pathway in patients who have been prescribed MAYZENT.

Preview

Thumbnail of Expand study animation.
 

THE EXPAND STUDY ANIMATION

A video highlighting key MAYZENT efficacy and safety data for the treatment of SPMS with active disease, as demonstrated in the pivotal phase III study, EXPAND.

View

 

Mayzent Switch tool
 

MAYZENT SWITCH TOOL

The MAYZENT switch tool provides guidance on how to safely switch patients to MAYZENT from other treatments.

View

Mayzent clinical protocol
 

MAYZENT CLINICAL PROTOCOL

The purpose of this document is to provide you with a template and useful information to support with the development of your local clinical protocol for MAYZENT treatment.

Preview

 

 

Indication: MAYZENT is indicated for the treatment of adult patients with SPMS with active disease evidenced by relapses or imaging features of inflammatory activity.1

SPMS, secondary progressive multiple sclerosis.

Reference:

  1. MAYZENT (siponimod) Summary of Product Characteristics.
Rate this content: 
No votes yet
UK | June 2021 | 103440
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]